Based on the protective role exerted by roxadustat in anemia, roxadustat has been proven to be beneficial in anemia patients with lower-risk myelodysplastic syndrome who has low EPO level (<400 m IU/mL) and receive 1–4 RBC units infusion per eight weeks (NCT03263091). This evidence concerns the gene EPO and anemia.